Therapy Detail

Therapy Name AC-93253 iodide + Gefitinib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AC-93253 iodide SRC Inhibitor 27 AC-93253 iodide is an inhibitor of SRC, which also results in reduced expression and phosphorylation of signaling molecules downstream of Src, potentially leading to decreased cell proliferation and inhibition of tumor growth (PMID: 29132432).
Gefitinib Iressa ZD1839 EGFR Inhibitor (Pan) 42 EGFR Inhibitor 1st gen 3 Iressa (gefitinib) is a first-generation EGFR inhibitor that binds EGFR and inhibits downstream signaling, potentially resulting in decreased growth of tumors with EGFR activation (PMID: 26980062, PMID: 25302162, PMID: 15284455). Iressa (gefitinib) is FDA approved for use in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung adenocarcinoma predicted - sensitive AC-93253 iodide + Gefitinib Preclinical - Cell culture Actionable In a preclinical study, AC-93253 iodide combined with Iressa (gefitinib) resulted in a synergistic effect, demonstrating growth inhibition of an Iressa (gefitinib)-resistant lung adenocarcinoma cell line in culture (PMID: 29132432). 29132432
Clinical Trial Phase Therapies Title Recruitment Status